Detalles de la búsqueda
1.
Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspective.
Cost Eff Resour Alloc
; 16: 17, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29773969
2.
External Validation of Health Economic Decision Models for Chronic Obstructive Pulmonary Disease (COPD): Report of the Third COPD Modeling Meeting.
Value Health
; 20(3): 397-403, 2017 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-28292484
3.
Patient Heterogeneity in Health Economic Decision Models for Chronic Obstructive Pulmonary Disease: Are Current Models Suitable to Evaluate Personalized Medicine?
Value Health
; 19(6): 800-810, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27712708
4.
The long-term clinical and economic benefits of treating advanced COPD patients with single-inhaler triple therapy in Quebec, Canada - the IMPACT trial.
Respir Med
; : 107694, 2024 Jun 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38844004
5.
Is single-inhaler triple therapy for COPD cost-effective in the UK? The IMPACT trial.
ERJ Open Res
; 8(1)2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-35198630
6.
Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis.
Adv Ther
; 39(9): 3957-3978, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35849317
7.
Cost-Effectiveness of Single- versus Multiple-Inhaler Triple Therapy in a UK COPD Population: The INTREPID Trial.
Int J Chron Obstruct Pulmon Dis
; 17: 2745-2755, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36317185
8.
Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT Trial.
Int J Chron Obstruct Pulmon Dis
; 17: 1633-1642, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35915738
9.
Lifetime Cost-effectiveness of Oral Semaglutide Versus Dulaglutide and Liraglutide in Patients With Type 2 Diabetes Inadequately Controlled With Oral Antidiabetics.
Clin Ther
; 43(11): 1812-1826.e7, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34728099
10.
Cost-effectiveness analysis of a single-inhaler triple therapy for COPD in the UK.
ERJ Open Res
; 7(1)2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-33778055
11.
Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial.
Curr Oncol
; 28(2): 1256-1261, 2021 03 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-33802634
12.
Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model.
Int J Chron Obstruct Pulmon Dis
; 16: 3105-3118, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34916789
13.
Cost-utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec healthcare system perspective.
J Med Econ
; 12(3): 246-58, 2009 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-19743942
14.
Long-term cost and utility consequences of short-term clinically important deterioration in patients with chronic obstructive pulmonary disease: results from the TORCH study.
Int J Chron Obstruct Pulmon Dis
; 14: 939-951, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31190781
15.
Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial.
Int J Chron Obstruct Pulmon Dis
; 14: 2681-2695, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31819401
16.
Cost-effectiveness and budget impact of liraglutide in type 2 diabetes patients with elevated cardiovascular risk: a US-managed care perspective.
Clinicoecon Outcomes Res
; 10: 791-803, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30532570
17.
Cost-effectiveness of umeclidinium as add-on to ICS/LABA therapy in COPD: A UK perspective.
Respir Med
; 145: 130-137, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30509701
18.
Once-Daily Triple Therapy in Patients with Advanced COPD: Healthcare Resource Utilization Data and Associated Costs from the FULFIL Trial.
Adv Ther
; 34(9): 2163-2172, 2017 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28875459
19.
Prediction models for exacerbations in different COPD patient populations: comparing results of five large data sources.
Int J Chron Obstruct Pulmon Dis
; 12: 3183-3194, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-29138546
20.
Statistical Modeling of Disease Progression for Chronic Obstructive Pulmonary Disease Using Data from the ECLIPSE Study.
Med Decis Making
; 37(4): 453-468, 2017 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-26449490